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Introduction
Recurrent pericarditis represents an important complica-
tion of acute pericarditis. Therapeutic approach during
recurrences consists of NSAID administration. However
steroid is often necessary to control disease flares. IL-1
inhibitors efficacy has been anecdotally described as
effective in the control of the disease in steroid-depen-
dent and Colchicine-resistant patients.
Objectives
To evaluate the long term response to treatment with
Anakinra (IL-1 receptor antagonist) in multicenter
cohort of patients affected by idiopathic recurrent
pericarditis.
Methods
Fifteen patients (12 pediatrics and 3 adults; M:F=11:4)
affected by idiopathic recurrent pericarditis and fol-
lowed by 6 different national referral centers were
enrolled in the study. The mean age was 22 years
(range 9-60 yrs); mean age at onset was 16 years (5-49
yrs), mean age at the beginning of treatment was 19
years (6-56 yrs). All patients received an initial dosage
of 1-2 mg/Kg/die. All the patients presented steroid-
dependence and 14 of them had received Colchicine
during history disease. Outcomes evaluated in our study
were i)response to Anakinra, defined as resolution of
pericardial symptoms associated to normalization of
laboratory-instrumental findings after first administra-
tion of the drug; ii)long term remission during IL-1
receptor antagonist regimen defined as absence of
relapses during monotherapy; iii)resolution after Ana-
kinra discontinuation.
Results
All the patients that received Anakinra during active
disease (13 pts) presented a dramatic therapeutic
response featured by a very rapid disappearance of pre-
cordial pain, fever, rub and normalization of acute phase
reactants within a few hours from drug administration.
Continuous therapy allowed rapid tapering and then dis-
continuation of steroid, Colchicine and NSAID adminis-
tration. During continuous daily treatment (mean
FU=11 months, range 5-17 months), no patient pre-
sented a relapse of the disease; 14 patients started taper-
ing and 8 of them experienced a relapse (mean time
since tapering start to relapse=9 months, range 2-17
months). In all patients, disease flare was successfully
and quickly controlled by daily full-dose administration
of Anakinra, without the requirement of any steroid
treatment. A total of 10 flares have been observed in
these 8 patients. In 5 patients Anakinra was successfully
discontinued after 24 months of treatment (range 17-32
months). The mean time of remission since the with-
drawn of the drug is now 12 months (range 2-24
months). At the last follow-up all patients were in
remission. Two patients are still receiving daily adminis-
tration of Anakinra as monotherapy. In 8 patients Ana-
kinra tapering is ongoing.
Conclusion
The long term use of Anakinra in monotherapy is
associated to a persistent control of clinical-laborator-
istic-instrumental features of idiopathic recurrent peri-
carditis. In almost 50% of the patients reactivation of
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